Mesa Labs declares $0.16 quarterly dividend payable Sept. 15 By Investing.com
Mesa Laboratories, Inc. (NASDAQ:MLAB) has declared a quarterly dividend of $0.16 per share, payable on September 15, 2026, to shareholders of record as of August 31, 2026. The company has a 24-year history of dividend payments, and its stock has surged 35% year-to-date, trading at $103.80, which InvestingPro analysis considers undervalued. Despite recent challenges like missed Q4 revenue estimates and a decline in its Biological Products Division, Jefferies raised its price target to $130 with a Buy rating, and Lyndsey Crennen was appointed as the new chief accounting officer.
Mesa Labs sets $0.16 quarterly dividend, payable Sept. 15
Mesa Labs (NASDAQ: MLAB) announced a regular quarterly dividend of $0.16 per share for its common stock. The dividend is scheduled to be paid on September 15, 2026, to shareholders of record as of August 31, 2026. The company specializes in designing and manufacturing life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device sectors.
Mesa Laboratories Keeps Quarterly Dividend at $0.16 per Share, Payable Sept. 15 to Shareholders of Record Aug. 31
Mesa Laboratories, Inc. announced that it will keep its regular quarterly dividend at $0.16 per share. This dividend is payable on September 15, 2026, to shareholders who are on record as of August 31, 2026. The announcement was made on July 6, 2026.
MLAB - Mesa Laboratories Inc Latest SEC Filings
This article provides the latest SEC filings information for Mesa Laboratories Inc (MLAB), detailing its financial metrics, stock performance data, and other key company statistics. It includes financial figures like market cap, income, sales, P/E ratio, dividend information, and institutional/insider ownership. The content also lists various stock performance indicators and analyst recommendations.
Price to book forward of Mesa Laboratories, Inc. – NASDAQ:MLAB
This article provides the "Price to book forward" value for Mesa Laboratories, Inc. (NASDAQ: MLAB). The content indicates a specific period and its corresponding value, along with change and percentage change. The article focuses solely on this financial metric for the company.
Enterprise value to EBITDA forward of Mesa Laboratories, Inc. – NASDAQ:MLAB
This article focuses on the enterprise value to EBITDA (forward) for Mesa Laboratories, Inc. (NASDAQ: MLAB). It appears to be a financial data snippet from a larger platform rather than a detailed analysis, providing a specific financial metric for the company.
Price to earnings forward of Mesa Laboratories, Inc. – MUN:MLI
This article provides the "Price to earnings forward" value for Mesa Laboratories, Inc. (MUN:MLI). The content is primarily a header and mentions that the market is currently closed with no trades. It also details various products, communities, and services offered by TradingView, which appears to be the platform hosting this data.
Price to sales forward of Mesa Laboratories, Inc. – MUN:MLI
This article provides the "price to sales forward" value for Mesa Laboratories, Inc. (MUN:MLI). The financial data is noted as being provided by ICE Data Services and FactSet, with SEC filings from Quartr. Details regarding the specific financial value are presented within the main content.
Price to earnings forward of Mesa Laboratories, Inc. – NASDAQ:MLAB
This article provides the "Price to earnings forward" metric for Mesa Laboratories, Inc. (NASDAQ: MLAB). The content primarily consists of navigation and boilerplate text from the TradingView platform, noting that the market is closed and no trades have occurred for the stock.
Mesa Laboratories, Inc. Actuals & Estimates (NASDAQ:MLAB)
This article provides an overview of Mesa Laboratories, Inc. (MLAB) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and details on recent earnings and revenue. The report also covers future earnings dates, dividend information, employee count, and EBITDA.
MLAB Forecast — Price Target — Prediction for 2027
This article provides a forecast for Mesa Laboratories, Inc. (MLAB) stock, including analyst price targets, historical performance data, and financial metrics. It highlights that analysts have a one-year price target ranging from $94.00 to $130.00 and details the company's recent earnings, revenue, and dividend information. The report also addresses frequently asked questions about MLAB's stock price, volatility, market cap, and upcoming earnings dates.
Form 4 Mesa Laboratories Inc For: 23 June By Investing.com
This article reports on a Form 4 filing for Mesa Laboratories Inc., dated June 23, with a publication date of June 24, 2026. The content is primarily a placeholder or an auto-generated reporting piece from Investing.com, accompanied by various market data and news headlines. It indicates general market data including indices, commodities, and bonds, and briefly mentions Mesa Laboratories (MLAB) with a +3.92% change.
Mesa Labs SVP Brian Archbold sells $225k in stock after RSU conversion By Investing.com
Brian Archbold, Senior Vice President of Operations at Mesa Laboratories Inc. (NASDAQ:MLAB), sold 2,516 shares of company stock for approximately $225,187 after converting restricted stock units and performance share units. The sale occurred on June 22, 2026, following recent acquisitions of 5,183 shares through RSUs and performance share units. After these transactions, Mr. Archbold directly holds 6,377 shares of Mesa Laboratories common stock.
Mesa Labs SVP Brian Archbold sells $225k in stock after RSU conversion By Investing.com
Mesa Laboratories Inc.'s SVP of Operations, Brian David Archbold, sold 2,516 shares for approximately $225,187 after converting restricted stock units (RSUs) and performance share units. Prior to the sale, he acquired 5,183 shares through RSU conversions and performance share unit releases. These transactions follow Mesa Labs' mixed recent news, including disappointing Q4 results, a raised price target from Jefferies, and changes in executive leadership.
Mesa Labs SVP Brian Archbold sells $225k in stock after RSU conversion
Brian David Archbold, SVP of Operations at Mesa Laboratories Inc. (NASDAQ:MLAB), sold approximately $225,187 worth of stock after converting restricted stock units and performance share units. The sale involved 2,516 shares at $89.502 per share on June 22, 2026. This followed his acquisition of 5,183 shares through RSU conversions and performance share unit releases on June 18, 2026.
Mesa Labs CAO Crennen sells $39,559 in MLAB shares
Mesa Laboratories' Chief Accounting Officer, Lyndsey Elizabeth Crennen, sold 442 shares of MLAB stock worth $39,559 to cover taxes on vested Restricted Stock Units and Performance Share Units. Prior to this sale, Crennen acquired 989 shares through RSU conversions and performance share unit releases. These transactions occurred amidst a 6.5% decline in Mesa Labs stock over the past week and recent mixed financial news for the company.
Mesa Labs SVP Brian Archbold sells $225k in stock after RSU conversion
Brian Archbold, Senior Vice President of Operations at Mesa Laboratories Inc. (NASDAQ:MLAB), sold 2,516 shares of company stock worth approximately $225,187. This sale followed his acquisition of 5,183 shares through the conversion of restricted stock units (RSUs) and performance share units (PSUs). Despite the recent stock decline, InvestingPro analysis suggests Mesa Laboratories is undervalued and has a history of consistent dividend payments.
Mesa Laboratories (MLAB) CAO reports RSU vesting and 442-share tax sale
Mesa Laboratories' CAO, Lyndsey Elizabeth Crennen, reported the vesting of restricted stock units (RSUs) and performance share units (PSUs), resulting in 726 shares of common stock and an additional 263-share grant. Subsequently, Crennen sold 442 shares of common stock at $89.502 per share to cover tax obligations related to the equity vesting. After these transactions, her direct holdings in Mesa Laboratories total 2,020 shares.
Mesa Labs CFO John Sakys sells $253k in company stock By Investing.com
Mesa Labs CFO John Sakys sold 2,827 shares of company stock worth approximately $253,022 to cover taxes related to vesting RSUs and PSUs. Prior to this sale, Sakys acquired 6,074 shares through vesting. The company has seen recent challenges in its Biological Products Division but received a boosted price target from Jefferies, and is undergoing leadership changes including the impending departure of CEO Gary Owens.
Form 4 Mesa Laboratories Inc For: 23 June By Investing.com
Investing.com has published a Form 4 for Mesa Laboratories Inc., dated June 23. This filing is available on their platform, which also provides various financial market data and news. The article indicates a slight dip in MLAB stock performance with a -1.47% change.
Mesa Laboratories (MLAB) CFO reports grants, RSU conversions and tax-cover share sale
Mesa Laboratories CFO John Sakys recently engaged in several equity transactions, including receiving a grant of 2,282 shares and exercising restricted stock units (RSUs) that converted into 3,792 shares in total. He subsequently sold 2,827 shares at an average price of $89.502 per share to cover tax obligations stemming from the RSU and performance share unit vesting, a transaction executed under a Rule 10b5-1 trading plan. Following these activities, Sakys directly holds 19,785 Mesa Laboratories shares, with an additional 50 shares held indirectly for his children.
Mesa Laboratories (MLAB) SVP exercises RSUs and sells 2,516 shares
Brian David Archbold, Senior Vice President of Operations at Mesa Laboratories (MLAB), recently engaged in significant stock transactions. He exercised restricted stock units (RSUs) for 3,324 shares and received an additional grant of 1,859 shares. Following these acquisitions, Archbold sold 2,516 shares of MLAB common stock on the open market at approximately $89.50 per share, retaining a direct holding of 6,377 shares.
Form 144 MESA LABORATORIES INC /CO/ For: 22 June By Investing.com
This article announces the filing of Form 144 for MESA LABORATORIES INC /CO/ on June 22nd. Form 144 is a notice of the intent to sell restricted securities. The brief notice was published by Investing.com.
MLAB (NASDAQ: MLAB) files Rule 144 for 2,827 vested shares via Fidelity
Mesa Laboratories Inc. (MLAB) has filed a Rule 144 notice for the proposed resale of 2,827 common shares, valued at $253,021.88, which are linked to the vesting of restricted stock. Fidelity Brokerage Services LLC is listed as the broker-dealer for this transaction. The filing also indicates previous sales of 1,223 shares on June 16, 2026, for $123,849.54 by John Sakys.
Form 144 MESA LABORATORIES INC /CO/ For: 22 June By Investing.com
This article announces the filing of Form 144 for MESA LABORATORIES INC /CO/ on June 22. It is a brief administrative notice from Investing.com, providing basic information about the filing and its publication time. The content also lists various market data and other news items, but these are extraneous to the main subject.
MLAB (NASDAQ: MLAB) insider sale notice — 2,516 shares disclosed
Mesa Laboratories (NASDAQ: MLAB) has filed a Form 144 notice to sell 2,516 shares of Common Stock, linked to a Restricted Stock Vesting event on June 18, 2026. The filing also reports that 1,151 shares were sold on June 16, 2026, for a value of $116,558.32. The proposed sale is considered neutral in sentiment and impact by Rhea-AI, indicating that while it's a notification to the market, it doesn't significantly alter the company's outlook.
[144] MESA LABORATORIES INC /CO/ SEC Filing
This article details an SEC Form 144 filing by Mesa Laboratories Inc. for a proposed sale of securities. The filing indicates a sale of 1223 shares of common stock with an aggregate market value of $123,849.54, acquired on June 15, 2026, through restricted stock vesting. Fidelity Brokerage Services LLC is listed as the broker for this NASDAQ-listed transaction.
MLAB SEC Filings - Mesa Laboratories 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Mesa Laboratories (MLAB) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent filings such as an 8-K press release, DEF 14A proxy statement, and several Form 4 insider transaction reports for executives related to RSU conversions and tax withholdings. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Mesa Laboratories CAO Lyndsey Crennen sells $11,949 in shares By Investing.com
Mesa Laboratories' Chief Accounting Officer, Lyndsey Crennen, sold 118 shares of the company's common stock for $11,949 to cover taxes on vested Restricted Stock Units. The sale occurred on June 16, 2026, and she now holds 1,473 shares. Despite a recent decline in stock price, shares have surged 25% over the past six months, and InvestingPro suggests MLAB is undervalued.
Mesa Laboratories (MLAB) CAO sells 118 shares to cover RSU tax obligations
Mesa Laboratories' Chief Accounting Officer, Lyndsey Elizabeth Crennen, sold 118 shares of common stock at an average price of $101.267 per share on June 16, 2026. This sale was conducted to cover tax obligations stemming from restricted stock units (RSUs) that vested on June 15, 2026, and was not a discretionary portfolio move. Following this transaction, she directly holds 1,473 shares of Mesa Laboratories common stock.
Mesa Laboratories (MLAB) SVP sells 1,151 shares in open-market trade
Mesa Laboratories Senior Vice President of Operations, Brian David Archbold, sold 1,151 shares of the company's common stock on June 16, 2026, at an average price of $101.267 per share. This open-market transaction, reported via a Form 4 SEC filing, leaves him with 3,710 shares directly held. The sale reflects a net-sell for the reporting period, impacting his direct holdings in MLAB.
Mesa Laboratories Inc (MLAB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Mesa Laboratories Inc (MLAB) has an earnings forecast score of 7.33, placing it 142nd out of 204 in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $95.00, with forecasts ranging from $75.00 to $115.00, and predominantly recommend a "Buy" for the stock. Expected revenue for the next quarter is $60.87 million, with an anticipated EPS of $0.03.
Mesa Laboratories Inc (MLAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Mesa Laboratories Inc (MLAB), categorizing its revenue by business segments and geographical regions. The company's revenue streams are primarily from Discrete Revenues-Consumables, which constitutes the largest portion, followed by Hardware and Software, and various services. Geographically, the United States accounts for the largest share of revenue, with a significant amount also coming from "Other" regions and China.
Insider Sell: Brian Archbold Sells Shares of Mesa Laboratories I
Brian Archbold, Senior Vice President of Operations at Mesa Laboratories Inc (MLAB), sold 1,151 shares of the company on June 16, 2026. Following this transaction, he now owns 3,710 shares. The stock is currently trading at $101.27 and is considered modestly undervalued with a price-to-GF-Value ratio of 0.87.
Mesa Labs CFO John Sakys sells $123,849 of company stock
Mesa Laboratories CFO John Sakys sold 1,223 shares of company stock for $123,849 to cover taxes related to vesting restricted stock units. Following the sale, Sakys directly holds 16,538 shares and indirectly holds 50 shares. This transaction occurred amidst recent news of Mesa Labs reporting Q4 results below expectations, a CEO departure, and a new chief accounting officer appointment, yet still receiving a raised price target from Jefferies.
Mesa Laboratories SVP Brian Archbold sells $116,558 in shares By Investing.com
Brian David Archbold, Senior Vice President of Operations at Mesa Laboratories Inc. (NASDAQ:MLAB), sold 1,151 shares of the company's common stock for $116,558 on June 16, 2026. Following the sale, Mr. Archbold directly owns 3,710 shares. This transaction occurs as Mesa Laboratories' stock has seen a 25% return over the past six months, despite recent Q4 results missing expectations and other leadership transitions.
Mesa Laboratories (MLAB) CFO sells 1,223 shares to cover RSU tax obligations
Mesa Laboratories CFO John Sakys sold 1,223 shares of company common stock on June 16, 2026, at $101.267 per share. This open-market sale was conducted to cover tax obligations arising from the vesting of restricted stock units on June 15, 2026. After the transaction, Sakys directly holds 16,538 shares and indirectly holds 50 shares for his children.
Mesa Laboratories Inc (MLAB) Shares Fall 4.2% -- What GF Score of 77 Tells Investors
Mesa Laboratories Inc (MLAB) shares dropped 4.2% to $99.29 on June 16, 2026, despite a year-to-date increase of 26.9%. The stock is considered undervalued with a GF Value of $115.97, offering a 14.4% upside. MLAB's GF Score of 77/100 indicates strong potential for long-term returns, with high marks in Valuation and Profitability, though Growth and Predictability ratings are lower.
Mesa Laboratories Promotes Lyndsey Crennen to Chief Accounting Officer
Mesa Laboratories has promoted longtime executive Lyndsey Crennen to Chief Accounting Officer from her previous role as Corporate Controller. Crennen, a CPA with over two decades of experience, will receive a base salary of $325,000, performance bonuses, and participate in the firm's long-term incentive plan. Analysts currently rate MLAB as a Hold with a $94.00 price target, while TipRanks' AI Analyst views it as Neutral due to strong cash generation offset by high valuation.
Mesa Laboratories (MLAB) CAO details stock, option and RSU holdings in Form 3
Mesa Laboratories' Chief Accounting Officer, Lyndsey Elizabeth Crennen, has filed an initial statement of beneficial ownership (Form 3), detailing her existing holdings in the company. The filing indicates direct ownership of 1,863 common shares, along with various non-qualified stock options and restricted stock units (RSUs) that vest over time. These holdings reflect her stake in MLAB, with no new open market purchases reported.
[144] MESA LABORATORIES INC /CO/ SEC Filing
This article is an SEC Filing Form 144 for Mesa Laboratories Inc. (MLAB) reporting a notice of proposed sale of securities. The filing details the sale of 3,706 shares of common stock with an aggregate market value of $375,295.50, acquired through restricted stock vesting on June 15, 2026. The transaction will be handled by Fidelity Brokerage Services LLC on the NASDAQ exchange.
Mesa Laboratories (NASDAQ: MLAB) SVP exercises options and receives 4,328 RSUs
Brian David Archbold, SVP Operations at Mesa Laboratories (NASDAQ: MLAB), reported significant equity compensation changes. On June 15, 2026, he exercised stock options to acquire 2,454 common shares at $104.08 each, increasing his direct common stock holdings to 4,861 shares. Additionally, Archbold received a grant of 4,328 Restricted Stock Units (RSUs) and had 1,780 Non Qualified Stock Options expire.
Mesa Laboratories appoints Lyndsey Crennen as chief accounting officer By Investing.com
Mesa Laboratories (NASDAQ:MLAB) has appointed Lyndsey Crennen as chief accounting officer, effective upon her new employment agreement. Crennen, 41, has over 20 years of experience, joining the company in 2018 and serving as corporate controller since 2022. She will receive an annual base salary of $325,000, eligible for bonuses and long-term incentive awards.
Mesa Laboratories appoints Lyndsey Crennen as chief accounting officer
Mesa Laboratories (NASDAQ:MLAB) has appointed Lyndsey Crennen as its new chief accounting officer, effective upon her new employment agreement. Crennen, with over 20 years of experience, previously served as corporate controller and held roles at Chipotle Mexican Grill and PricewaterhouseCoopers. Her compensation package includes an annual base salary of $325,000, eligibility for a short-term incentive bonus, and long-term incentive awards.
Mesa Laboratories appoints Lyndsey Crennen as chief accounting officer By Investing.com
Mesa Laboratories, Inc. has announced the appointment of Lyndsey Crennen as chief accounting officer, effective upon her new employment agreement. Crennen, who has over 20 years of accounting experience, previously served as corporate controller since 2022 and held roles at Chipotle Mexican Grill and PricewaterhouseCoopers. Her compensation package will include an annual base salary of $325,000, eligibility for a short-term incentive bonus, and long-term incentive awards.
Mesa Laboratories (MLAB) appoints Lyndsey Crennen Chief Accounting Officer
Mesa Laboratories (MLAB) has appointed Lyndsey Crennen as Chief Accounting Officer, effective upon her entry into a new Employment Agreement around June 26, 2026. Crennen, who has over 20 years of accounting experience and has served as Corporate Controller since 2022, will receive a base salary of $325,000, be eligible for a 40% annual cash bonus, and a long-term incentive target award of $300,000. The company confirmed there are no related-party transactions or family relationships requiring disclosure regarding her appointment.
Mesa Laboratories, Inc. Announces Appointment of Lyndsey Crennen as Chief Accounting Officer
Mesa Laboratories, Inc. has officially appointed Lyndsey Crennen as its new Chief Accounting Officer, effective upon the start of her Employment Agreement. Crennen brings over 20 years of experience in accounting, having previously served as Corporate Controller at Mesa since 2022 and holding various roles at Chipotle Mexican Grill and PricewaterhouseCoopers LLP. She holds a B.S. degree in accounting and finance and is a Certified Public Accountant.
Mesa Laboratories (MLAB) CFO exercises awards and receives 8,416 RSUs
Mesa Laboratories CFO John Sakys recently reported significant equity changes. He exercised derivative awards to acquire 2,717 common shares, increasing his direct holdings to 17,761 shares, and was granted 8,416 restricted stock units. Additionally, 3,951 non-qualified stock options with an exercise price of $226.72 expired.
Mesa Laboratories : Annual Report for Fiscal Year Ending 03-31, 2026 (Form 10-K)
Mesa Laboratories has released its Annual Report for the fiscal year ending March 31, 2026, detailing financial performance across its four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The company reported overall revenue growth of 3.4% and a significant increase in net income compared to the previous fiscal year. The report also highlights strategic initiatives focusing on organic and inorganic growth, operating efficiency through the "Mesa Way" system, and talent retention, while addressing challenges like foreign currency fluctuations and macroeconomic conditions in China.
Mesa Laboratories (NASDAQ: MLAB) outlines global segments, GKE deal and key risks
Mesa Laboratories (NASDAQ: MLAB) has detailed its business, strategy, and risk factors in its annual 10-K filing. The company, a global provider of life sciences tools, operates four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. The report highlights the acquisition of GKE for $87,187 to expand its sterilization indicators and discusses a decrease in backlog to $33.6 million, attributing it to timing in Clinical Genomics and normalized sterilization orders.
